Alesi Surgical Raises £7M To Advance Surgical Smoke Management Technology

Surgical smoke is generated in the majority of procedures worldwide, impacting visibility for surgeons and exposing patients and staff to potentially harmful particles, including viruses, bacteria and chemicals. Despite the risks adoption of traditional smoke management systems has been limited due to their bulky and disruptive nature.

Alesi Surgical’s proprietary Ultravision platform offers a different approach, using electrostatic precipitation to remove smoke at the point of creation rather than relying on suction-based systems.

Its first-generation system has already been used in over 50,000 laparoscopic and robotic procedures across Europe, the US, and Japan, demonstrating significantly faster smoke removal compared to conventional technologies.

The technology also enables surgeons to operate at lower abdominal pressure, reducing CO₂ usage and improving patient outcomes, recovery times, and overall procedure efficiency.

Read Also - Bubble Robotics Raises $5M Pre-seed To Scale Autonomous Ocean Robotics

The company’s next-generation Ultravision2 system extends these benefits to open surgeries and integrates advanced surgical tools with smoke management capabilities.

The new funding will support Alesi Surgical’s global expansion and continued development of its Ultravision2 platform as regulatory pressure increases to adopt safer smoke-free surgical environments.

According to Dr Dominic Griffiths, Founder and CEO of Alesi Surgical, while electrosurgical tools have transformed modern surgery, they also produce surgical smoke that can reduce visibility, impact efficiency, and pose health risks to operating theatre staff.

“For years, available solutions have required trade-offs between effectiveness and workflow disruption, slowing adoption across the industry.

As awareness grows that smoke management is integral to surgical safety and efficiency, solutions that tackle smoke at its source, such as Ultravision2 which is FDA-approved and CE-marked, are becoming increasingly important for supporting the next generation of minimally invasive and robotic procedures.”

Isobel Egemole, Investment Director at IW Capital says “Alesi Surgical offers a fundamentally different approach to smoke management that addresses the problem at its source. As the industry moves toward smoke free operating theatres becoming the norm Ultravision2 is well positioned to play a key role.”

About Alesi Surgical

Alesi Surgical, founded in 2009 develops technologies to improve the safety and efficiency of surgical procedures. A spin-out from WIMAT, the company gained FDA clearance for its Ultravision2 system, which combines electrosurgery with advanced smoke control to enhance surgical visibility, outcomes and operating theatre safety.